RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+28.15%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$1.31B
AUM Growth
+$1.31B
(+9.2%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-10.7%
Top 10 Holdings %
Top 10 Hldgs %
78.43%
Holding
36
New
9
Increased
2
Reduced
10
Closed
5
Top Buys
| 1 |
TG Therapeutics
TGTX
|
$35.1M |
| 2 |
Solid Biosciences
SLDB
|
$20.2M |
| 3 |
Clearside Biomedical
CLSD
|
$16.4M |
| 4 |
Gyre Therapeutics
GYRE
|
$13.3M |
| 5 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$13.3M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$87.6M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$42.1M |
| 3 |
InflaRx
IFRX
|
$36.2M |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$22.7M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$17.7M |
Sector Composition
| 1 | Healthcare | 97.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Krystal Biotech
KRYS
$4.27B
| $5.01M | 0.38% | 496,071 -203,929 | -29% | -$2.06M |
|
|
CBIO
27
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $4.12M | 0.32% | +253,547 | New | +$4.12M |
|
28
Protara Therapeutics
TARA
$120M
| $3.34M | 0.26% | 1,337,462 | – | – |
|
|
GTHX
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $1.48M | 0.11% | 40,000 -119,780 | -75% | -$4.44M |
|
30
PDS Biotechnology
PDSB
$57.8M
| $337K | 0.03% | +285,491 | New | +$337K |
|
|
CTIC
31
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $222K | 0.02% | +56,951 | New | +$222K |
|
32
argenx
ARGX
$43.6B
| – | – | -75,816 | Closed | -$4.79M |
|
|
KDMN
33
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – | -6,269,342 | Closed | -$22.7M |
|
|
CHMA
34
DELISTED
Chiasma, Inc. Common Stock
CHMA
| – | – | -1,176,806 | Closed | -$2M |
|
|
ACHN
35
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| – | – | -585,890 | Closed | -$1.69M |
|
|
CMTA
36
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| – | – | -585,403 | Closed | -$11.1M |
|